Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD-1 inhibition in preclinical models of CLDN18.2-expressing cancers

December 12, 2024December 12, 2024

Posters & Oral Presentations

by Elevation Oncology

Presented at ESMO Immuno-Oncology Annual Congress 2024

Presenting Author: Thomas O’Hare

Save this Press Release

Download PDF

Other Related Resources

October 16, 2020February 22, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More

September 29, 2020February 22, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More

October 26, 2020March 1, 2021

Posters & Oral Presentations

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements Read More

January 15, 2021April 7, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More

March 29, 2021April 8, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions Read More

April 10, 2021April 7, 2021

Posters & Oral Presentations

Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions Read More